EuroPCR: Renal denervation devices take center stage

May 18, 2012 by MassDevice staff

Renal denervation systems, perhaps the hottest medical device innovation space this year, grab the spotlight at this year's EuroPCR conference in Paris.

EuroPCR logo

 Renal denervation hogs the spotlight
Renal denervation systems, used to ablate the sympathetic nerves near the kidneys to control medication-resistant hypertension, got their own track at this year's EuroPCR conference in Paris, where device titans showed off their devices and smaller companies hinted at things to come.

Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ) each unveiled new study results, vying for rank in the closely watched race to corner the market.

Sign up to get our free newsletters delivered right to your inbox.

St. Jude announced CE Mark approval in the European Union for its Enlightn system on the opening day of the conference, later releasing early study results that hinted at a much greater reduction in blood pressure than achieved in by Medtronic's Symplicity system in the same time-frame. Medtronic responded by dubbing the news "interesting," but merely "hypothesis-generating," noting that further studies are needed to draw any solid conclusions.